27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
- The Australian Therapeutic Goods Administration has granted provisional marketing authorization for Vir Biotechnology Inc's (NASDAQ:VIR) for sotrovimab, a monoclonal antibody for COVID-19.
- The approval covers adults and adolescents who do not require initiation of oxygen due to COVID-19 and are at increased risk of progression to hospitalization or death.
- Vir Biotechnology developed sotrovimab in partnership with GlaxoSmithKline plc (NYSE:GSK).
- It is authorized for emergency use in the U.S. and has received a positive scientific opinion from CHMP in the European Union.
- Price Action: VIR stock is up 1.14%% at $47.00, while GSK stock is down 0.55% at $41.62 during the market session on the last check Monday.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!